First Page | Meta Content | |
---|---|---|
Document Date: 2013-05-08 10:55:04Open Document File Size: 395,12 KBShare Result on FacebookCityBrussels / /CompanyEuropean Biopharmaceutical Enterprises / MoCA Working Group / Steering Group / /ContinentEurope / /CountryHungary / Belgium / France / Austria / Netherlands / Italy / Portugal / Estonia / Malta / Finland / Spain / / /FacilityBelgian National Institute / /IndustryTermbiopharmaceutical / project / biotechnology / pharmaceutical industry / biotechnology products / orphan medicinal product / medicinal product / manufacturing / biotechnology arm / environmental products / pharmaceutical / chemicals / medicinal products / orphan medicinal products / food / /MedicalConditionrare diseases / /OrganizationStanding Committee of European Doctors / European Association for Bio-industries / EuropaBio-EBE Joint Task Force on Rare Diseases / Belgian Government / European Association for Bioindustries / European Confederation / European Commission / European Federation of Pharmaceutical Industries and Associations / European Union / European Organisation for Rare Diseases / Belgian National Institute for Health and Disability Insurance / /PersonWills Hughes-Wilson / Tajani / / /PositionRosalind Travers Communications Manager / editor / Vice-President / EC Directorate General / Manager / EFPIA Phone / Manager / EuropaBio Phone / chair / r.travers@europabio.org Or Nicholas Elles Communications Manager / /ProgrammingLanguageEC / /Technologybiotechnology / GSM / /SocialTag |